PD-L1和PD-1作为治疗结直肠癌的免疫检查新靶点的研究进展  

Research progress of PD-L1 and PD-1 in new immune checkpoints as a target for colorectal cancer treatment

作　　者：李甜甜 刘斌[1,2,3] 王丽[1,2] 苏勤军[1,3] 范钰 Li Tiantian;Liu Bin;Wang Li;Su Qinjun;Fan Yu(Department of Pathology,General Hospital of Lanzhou Military Command,Gansu Lanzhou 730050,China;Institute of Pathology,Foundamental Medical College of Lanzhou University,Gansu Lanzhou 730030,China;Key Laboratory of Stem Cell and Gene Medicine,Gansu Lanzhou 730050,China;Foundamental Medical College of Gansu University of Traditional Chinese Medicine,Gansu Lanzhou 730000,China.)

机构地区：[1]中国人民解放军兰州军区兰州总医院病理科,甘肃兰州730050 [2]兰州大学基础医学院病理研究所,甘肃兰州730030 [3]甘肃省干细胞与基因药物重点实验室,甘肃兰州730050 [4]甘肃中医药大学基础医学院,甘肃兰州730000

出　　处：《现代肿瘤医学》2018年第11期1803-1807,共5页Journal of Modern Oncology

摘　　要：免疫抗癌疗法是一种新的治疗实体肿瘤的方法。在这个新的领域,免疫系统里作为负向调节因子的免疫检查位点,在抗肿瘤免疫反应领域中起着重要的作用。因此,诸如抗细胞毒性T淋巴细胞相关抗原4(CTLA-4)、程序性细胞死亡蛋白(PD-1)、程序性细胞死亡蛋白配体1(PD-L1),现在已经研发出了针对前述这三者免疫检查位点的阻断因子,用于抗肿瘤的药物,在临床前期研究和临床研究中有着可喜的成果。本文综述关于在结直肠癌中免疫检查位点阻断剂的生物背景和临床研发最新进展。关于阻断PD-1和PD-L1的临床前期试验结果的前景令人充满希望,尤其是在带有微卫星不稳定性(MSI)的结直肠癌患者中更加明显。接下来进一步深入开展的临床试验将证实这些初步结果,并且评估这二者联合治疗方法的可行性和确认这两个生物标记物作为免疫检查位点阻断剂的效应在哪些人群中更有可能受益或更加抵抗。Anti-tumor immunity is a new line of research for the treatment of patients with solid tumors.In this field,negative regulators of the immune system called immune checkpoints play an important role in limiting anti-tumor immunologic responses.For this reason,immune checkpoint-inhibiting agents,such as those directed against cytotoxic T-lymphocyte antigen 4（ CTLA-4） and programmed death-1 receptor（ PD-1） and its ligand/receptor PD-L1,have been developed as anti-tumor drugs,producing interesting results in preclinical and clinical studies.We present an updated review of the biological background and clinical development of immune checkpoint inhibitors in colorectal cancer（ CRC）.Early trial results on PD-1 and PD-L1 blockade appear promising,especially in CRC patients with microsatellite instability（ MSI）.Clinical trials are ongoing to confirm these preliminary results,evaluate combination strategies and identify biomarkers to predict or select which patients are most likely to benefit from,or show resistance to the effects of checkpoint inhibition.

关 键 词：结直肠癌 免疫检查位点阻断剂 微卫星不稳定性(MSI) 程序性细胞死亡蛋白1(PD-1) 程序性细胞死亡蛋白配体1(PD-L1) 

分 类 号：R730.35[医药卫生—肿瘤] R730.37[医药卫生—临床医学]